Hot Features
プレミアム
Sangamo Therapeutics Inc (0R1D)
LSE
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-05-25 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -1.92k | 334.48 | Sale to Issuer | 0.17 | 202.66k | -0.94% |
| 2026-05-25 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -4.04k | 703.47 | Sale to Issuer | 0.17 | 568.62k | -0.70% |
| 2026-05-25 | Dr. Alexander D. MacraeCEO, President & Director | -12.61k | 2.20k | Sale to Issuer | 0.17 | 1.65M | -0.76% |
| 2026-05-25 | Dr. Gregory DavisHead of Research & Technology | -1.63k | 284.11 | Sale to Issuer | 0.17 | 81.02k | -1.97% |
| 2026-05-25 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -4.04k | 703.47 | Sale to Issuer | 0.17 | 249.98k | -1.59% |
| 2026-04-22 | Dr. Gregory DavisHead of Research & Technology | -69.83k | 17.69k | 売り | 0.25 | 77.99k | -47.24% |
| 2026-04-21 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -345.94k | 89.18k | 売り | 0.26 | 242.77k | -58.76% |
| 2026-02-24 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -14.42k | 6.78k | Sale to Issuer | 0.47 | 588.71k | -2.39% |
| 2026-02-24 | Dr. Alexander D. MacraeCEO, President & Director | -38.93k | 18.31k | Sale to Issuer | 0.47 | 1.63M | -2.34% |
| 2026-02-24 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -14.00k | 6.59k | Sale to Issuer | 0.47 | 561.41k | -2.43% |
| 2026-02-24 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -5.79k | 2.72k | Sale to Issuer | 0.47 | 199.92k | -2.81% |
| 2026-02-24 | Dr. Gregory DavisHead of Research & Technology | -5.95k | 2.80k | Sale to Issuer | 0.47 | 147.82k | -3.87% |
| 2026-01-22 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -7.72k | 3.08k | Sale to Issuer | 0.40 | 180.62k | -4.10% |
| 2026-01-22 | Ms. Prathyusha Duraibabuインサイダー | -36.68k | 14.62k | Sale to Issuer | 0.40 | 535.03k | -6.42% |
| 2026-01-22 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -36.68k | 14.62k | Sale to Issuer | 0.40 | 541.40k | -6.34% |
| 2026-01-22 | Dr. Alexander D. MacraeCEO, President & Director | -102.95k | 41.03k | Sale to Issuer | 0.40 | 1.56M | -6.20% |
| 2026-01-22 | Dr. Gregory DavisHead of Research & Technology | -7.72k | 3.08k | Sale to Issuer | 0.40 | 139.31k | -5.25% |
| 2026-01-22 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -36.68k | 14.62k | Sale to Issuer | 0.40 | 568.12k | -6.06% |
| 2025-11-24 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -578.00 | 240.79 | Sale to Issuer | 0.42 | 245.72k | -0.23% |
| 2025-11-24 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -2.04k | 847.78 | Sale to Issuer | 0.42 | 566.95k | -0.36% |
| 2025-11-24 | Dr. Alexander D. MacraeCEO, President & Director | -7.49k | 3.12k | Sale to Issuer | 0.42 | 1.63M | -0.46% |
| 2025-11-24 | Ms. Prathyusha Duraibabuインサイダー | -2.54k | 1.06k | Sale to Issuer | 0.42 | 560.58k | -0.45% |
| 2025-11-24 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -2.54k | 1.06k | Sale to Issuer | 0.42 | 583.66k | -0.43% |
| 2025-11-24 | Dr. Gregory DavisHead of Research & Technology | -723.00 | 301.20 | Sale to Issuer | 0.42 | 139.70k | -0.51% |
| 2025-10-22 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -6.71k | 4.43k | Sale to Issuer | 0.66 | 246.30k | -2.65% |
| 2025-10-22 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -44.12k | 29.12k | Sale to Issuer | 0.66 | 487.04k | -8.31% |
| 2025-10-22 | Dr. Alexander D. MacraeCEO, President & Director | -126.95k | 83.79k | Sale to Issuer | 0.66 | 1.40M | -8.30% |
| 2025-10-22 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -43.74k | 28.87k | Sale to Issuer | 0.66 | 503.27k | -8.00% |
| 2025-10-22 | Ms. Prathyusha Duraibabuインサイダー | -45.23k | 29.85k | Sale to Issuer | 0.66 | 480.18k | -8.61% |
| 2025-10-22 | Dr. Gregory DavisHead of Research & Technology | -6.71k | 4.43k | Sale to Issuer | 0.66 | 103.25k | -6.10% |
| 2025-08-24 | Dr. Alexander D. MacraeCEO, President & Director | -7.49k | 4.39k | Sale to Issuer | 0.59 | 1.28M | -0.58% |
| 2025-08-24 | Dr. Gregory DavisHead of Research & Technology | -723.00 | 423.89 | Sale to Issuer | 0.59 | 109.95k | -0.65% |
| 2025-08-24 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -1.43k | 840.75 | Sale to Issuer | 0.59 | 442.10k | -0.32% |
| 2025-08-24 | Ms. Prathyusha Duraibabuインサイダー | -1.79k | 1.05k | Sale to Issuer | 0.59 | 436.34k | -0.41% |
| 2025-08-24 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -1.79k | 1.05k | Sale to Issuer | 0.59 | 457.94k | -0.39% |
| 2025-07-22 | Dr. Alexander D. MacraeCEO, President & Director | -126.95k | 60.91k | Sale to Issuer | 0.48 | 1.27M | -9.07% |
| 2025-07-22 | Ms. Prathyusha Duraibabuインサイダー | -31.87k | 15.29k | Sale to Issuer | 0.48 | 433.12k | -6.85% |
| 2025-07-22 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -31.87k | 15.29k | Sale to Issuer | 0.48 | 439.53k | -6.76% |
| 2025-07-22 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -31.87k | 15.29k | Sale to Issuer | 0.48 | 454.73k | -6.55% |
| 2025-07-22 | Dr. Gregory DavisHead of Research & Technology | -6.71k | 3.22k | Sale to Issuer | 0.48 | 108.65k | -5.81% |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
